Fate Therapeutics, Inc.
FATE
NASDAQ·Healthcare·Biotechnology·Mkt cap $289.1M
$2.48
▲ +2.48%
P/E
-2.36
Mkt Cap
$289.1M
52-Wk Range
$0.93–$3.23
52-Week Range
$0.93 - $3.23
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 156.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Off-the-shelf iPSC-derived cell therapy platform eliminating patient-specific manufacturing
- Proprietary genetic engineering and cell programming technology for enhanced therapeutic properties
- Strategic partnerships with Ono Pharmaceutical, Juno Therapeutics, and Janssen providing validation and commercialization pathways
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Mild headwinds expected
Clinical trial advancement and positive efficacy data for lead pipeline candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+29.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying FATE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 13, 2026
Reported EPS of -$0.25 vs -$0.25 consensus (+1.4% surprise). Revenue of $2.1M vs $1.9M expected (+7.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1.4%
Revenue trend · last 8Q
—
+11%
-15%
-72%
-43%
-26%
-20%
+9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.1M
$1.9M
$1.6M
$1.9M
$1.7M
$1.4M
$1.3M
$2.1M
Margins · last 8Q
Gross
0.0%
Profit
-1448.6%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 14, 2026
vs Industry
How FATE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related